Hospital
Sutter Valley Hospitals
Sutter Valley Hospitals was paid $15.54M by Medicaid between Jan 2018 and Dec 2024, across 131 billing codes. Its largest line is 0450, Emergency room services — 19% of everything it billed.
33Billing provider infoSUTTER VALLEY HOSPITALS
AUBURN, CA 95602
AUBURN, CA 95602
33aNPI1194774299assigned 05/08/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$15.54M
24GClaims266,223
24DCodes billed131
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#141 of 410
Median peer was paid$6.90M
This provider vs. median2.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 38,655 | $2.16M | |
| 2019 | 36,101 | $1.94M | |
| 2020 | 26,780 | $1.34M | |
| 2021 | 36,515 | $2.30M | |
| 2022 | 40,541 | $2.48M | |
| 2023 | 49,820 | $2.88M | |
| 2024incomplete | 37,811 | $2.43M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 19% | 28,520 | 25,193 | $2.91M |
| 99199 | Unlisted special service, procedure or report | 12% | 15,519 | 13,402 | $1.84M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 6.0% | 7,118 | 6,237 | $938K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.2% | 7,701 | 7,029 | $806K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.5% | 1,751 | 1,693 | $701K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.7% | 1,938 | 1,864 | $568K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.8% | 1,966 | 1,921 | $441K |
| 0250 | 2.8% | 8,917 | 4,133 | $432K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 2.8% | 5,942 | 5,191 | $429K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.7% | 3,665 | 3,361 | $419K |
| 80053 | Comprehensive metabolic panel | 2.6% | 13,784 | 12,427 | $408K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.4% | 4,710 | 4,522 | $379K |
119 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.9% | 6,062 | $296K |
| 82077 | 1.8% | 2,152 | $285K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 2,106 | $267K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.6% | 18,648 | $247K |
| J3490 | Unclassified drugs | 1.5% | 11,720 | $236K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | 1.3% | 6,059 | $206K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 962 | $193K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 3,964 | $182K |
| 71046 | Radiologic examination, chest; 2 views | 1.2% | 3,931 | $181K |
| Z7502 | 1.1% | 4,681 | $177K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 1.1% | 4,167 | $168K |
| 80143 | 1.1% | 1,319 | $166K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 3,341 | $158K |
| 80179 | 1.0% | 1,285 | $157K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,150 | $134K |
| 71045 | Radiologic examination, chest; single view | <1% | 4,424 | $119K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,043 | $108K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 400 | $108K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,207 | $99K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,858 | $94K |
| 96376 | <1% | 388 | $94K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 7,094 | $91K |
| 99283 | Emergency room visit (moderate) | <1% | 1,372 | $83K |
| 84484 | <1% | 4,622 | $76K | |
| 83690 | <1% | 5,159 | $63K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 269 | $61K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,104 | $54K |
| 73610 | <1% | 916 | $51K | |
| 87040 | <1% | 2,220 | $50K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 885 | $48K |
| 73630 | <1% | 931 | $48K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,796 | $46K |
| 83880 | <1% | 1,093 | $46K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,268 | $44K |
| 81001 | <1% | 6,303 | $41K | |
| 0270 | <1% | 998 | $38K | |
| 81025 | <1% | 3,497 | $35K | |
| 83735 | <1% | 2,793 | $32K | |
| 73110 | <1% | 577 | $31K | |
| 83605 | <1% | 1,742 | $30K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 809 | $30K |
| 73562 | <1% | 615 | $29K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,980 | $29K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 242 | $28K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 699 | $27K |
| 82803 | <1% | 983 | $26K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 50 | $25K |
| 73030 | <1% | 471 | $25K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 340 | $24K |
| 81003 | <1% | 3,886 | $23K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 324 | $22K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 753 | $21K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,569 | $21K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 41 | $20K |
| 90715 | <1% | 273 | $19K | |
| 73130 | <1% | 306 | $18K | |
| 99284 | Emergency room visit (serious) | <1% | 235 | $18K |
| 82330 | <1% | 690 | $15K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 56 | $15K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,085 | $13K |
| 87634 | <1% | 111 | $11K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 467 | $11K |
| 87077 | <1% | 1,109 | $11K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,014 | $10K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 70 | $10K |
| 87186 | <1% | 1,106 | $10K | |
| 71250 | <1% | 53 | $10K | |
| 85610 | <1% | 1,594 | $10K | |
| 99285 | Emergency room visit (most serious) | <1% | 61 | $9K |
| 93971 | <1% | 30 | $8K | |
| 85379 | <1% | 371 | $7K | |
| 87430 | <1% | 370 | $7K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 682 | $6K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 507 | $6K |
| 76830 | Ultrasound, transvaginal | <1% | 26 | $5K |
| 87400 | <1% | 427 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 333 | $5K |
| 87081 | <1% | 347 | $5K | |
| 82947 | <1% | 669 | $5K | |
| 84702 | <1% | 341 | $3K | |
| 73502 | <1% | 56 | $3K | |
| J0137 | Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg | <1% | 110 | $3K |
| 85730 | <1% | 267 | $2K | |
| 0510 | <1% | 277 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 235 | $2K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 138 | $2K |
| 73140 | <1% | 27 | $1K | |
| 84132 | <1% | 325 | $917.80 | |
| 84295 | <1% | 299 | $871.62 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 72 | $712.53 |
| 87070 | <1% | 42 | $664.43 | |
| 72100 | <1% | 12 | $642.45 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 73 | $526.90 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 16 | $517.76 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 14 | $477.06 |
| 84703 | <1% | 331 | $466.67 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 38 | $349.03 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 13 | $311.34 |
| 86900 | <1% | 59 | $302.13 | |
| 86901 | <1% | 53 | $291.72 | |
| 87147 | <1% | 21 | $256.75 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 12 | $230.35 |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 12 | $205.58 |
| 87420 | <1% | 14 | $200.98 | |
| 0761 | <1% | 13 | $190.16 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 171 | $165.95 |
| J2704 | Injection, propofol, 10 mg | <1% | 26 | $165.03 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 13 | $151.83 |
| 86308 | <1% | 15 | $140.23 | |
| 87205 | <1% | 15 | $136.35 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 14 | $119.38 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 19 | $107.04 |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 39 | $80.02 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 13 | $50.19 |
| 85652 | <1% | 14 | $49.73 | |
| 86140 | <1% | 12 | $47.08 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 19 | $5.88 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 52 | $2.34 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 140 | $1.62 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCONFORTI, JAMES (PRESIDENT/CEO)
Parent organizationSUTTER VALLEY HOSPITALS
| Provider | Location | Paid |
|---|---|---|
| Sutter Valley Hospitals | Roseville, CA | $81.16M |
| Sutter Valley Hospitals | Vallejo, CA | $33.28M |
| Sutter Valley Hospitals | Davis, CA | $20.04M |
| Sutter Valley Hospitals | Jackson, CA | $11.20M |
| Sutter Valley Hospitals | Sacramento, CA | $3.16M |
| Sutter Valley Hospitals | Auburn, CA | $165K |
| Sutter Valley Hospitals | Auburn, CA | $25K |
| Sutter Valley Hospitals | Sacramento, CA | $71.31 |
| Sutter Valley Hospitals | Roseville, CA | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.